Last update Jan. 27, 2021


Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Recombinant-type of alfa-L-iduronidase that is used in enzyme replacement therapy in patients with Mucopolysaccharidosis I (MPS I).
Intravenous administration once a week.

Its high molecular weight explains the null passage observed in the milk of a nursing mother who had received weekly doses of Laronidase for three months, while she was breastfeeding. No physical or developmental problems in infants in the short or long term were observed (Castorina 2015).

Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant plasma.


We do not have alternatives for Laronidase.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Laronidase is also known as

Laronidase in other languages or writings:


Main tradenames from several countries containing Laronidase in its composition:


Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 69.900 - 83.000 daltons
VD 0.6 l/Kg
1.5 - 3.6 hours


  1. EMA. Laronidase. Drug Summary. 2016 Full text (in our servers)
  2. EMA. Laronidasa. Ficha técnica. 2016 Full text (in our servers)
  3. Castorina M, Antuzzi D, Richards SM, Cox GF, Xue Y. Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement. therapy. Clin Exp Obstet Gynecol. 2015 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM